Results 261 to 270 of about 781,057 (345)
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong +3 more
wiley +1 more source
Systems biology and microbiome innovations for personalized diabetic retinopathy management. [PDF]
NPJ Syst Biol ApplAminian-Dehkordi J +3 more
europepmc +1 more source
Diabetic kidney disease, biomarkers, and finerenone
Diabetes, Obesity and Metabolism, EarlyView.Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley +1 more source
Machine learning-based prediction of diabetic retinopathy from pupillary abnormalities in a South Indian population. [PDF]
PLoS OneSurya J +6 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Glucocorticoids (GCs) are widely utilised for the treatment of inflammatory and autoimmune conditions but often precipitate significant hyperglycaemia. People with type 1 diabetes (PWT1D) may be particularly affected due to the challenges of adjusting insulin dosing, for which recommendations remain unclear.
Alexandra Katz +8 more
wiley +1 more source